体外二氧化碳清除辅助超保护性通气治疗急性呼吸窘迫综合征的可行性与安全性:SUPERNOVA研究
SUPERNOVA是一项前瞻性多中心国际2期研究,纳入95例中度ARDS患者,评估ECCO2R辅助超保护性通气(VT 4 mL/kg、PPLAT≤25 cmH2O)的可行性与安全性。主要终点为达到超保护性通气且PaCO2较基线升高不超过20%、动脉pH>7.30的患者比例。结果显示8小时和24小时达到该终点的比例分别为78%(74/95,95%CI 68-89%)和82%(78/95,95%CI 76-88%)。ECCO2R维持5[3-8]天,报告6例严重不良事件(其中2例归因于ECCO2R:脑出血和气胸),39%的患者发生ECCO2R相关不良事件;第28天存活69例(73%),出院存活59例(62%)。作者结论认为ECCO2R辅助超保护性通气可行,需随机临床试验评估总体获益与危害。
要点
- 95例中度ARDS患者中,8小时和24小时达到超保护性通气且PaCO2升高≤20%、pH>7.30的比例分别为78%(74/95,95%CI 68-89%)和82%(78/95,95%CI 76-88%)。
- ECCO2R维持时间为5[3-8]天;研究使用低CO2清除装置(膜肺横截面积0.59 m2;流量300-500 mL/min)和高CO2清除装置(膜肺横截面积1.30 m2;流量800-1000 mL/min)。
- 报告6例严重不良事件,其中2例归因于ECCO2R(脑出血和气胸);39%的患者发生ECCO2R相关不良事件。
- 第28天存活69例(73%),出院存活59例(62%)。
- 作者结论认为ECCO2R辅助超保护性通气可行,但需随机临床试验评估总体获益与危害。
适用人群与场景
- 中度急性呼吸窘迫综合征(ARDS)患者。
诊断标准与关键阈值
- 超保护性通气目标:潮气量(VT)4 mL/kg,平台压(PPLAT)≤25 cmH2O。
- 主要终点达标条件:达到超保护性通气且PaCO2较基线升高不超过20%,动脉pH>7.30。
处置流程与药物剂量
- 使用ECCO2R辅助实现超保护性通气:低CO2清除装置(膜肺横截面积0.59 m2;流量300-500 mL/min)或高CO2清除装置(膜肺横截面积1.30 m2;流量800-1000 mL/min)。
- ECCO2R维持5[3-8]天。
红旗征与不能漏的情况
- ECCO2R相关严重不良事件包括脑出血和气胸。
研究设计与关键结果
- 前瞻性多中心国际2期研究,纳入95例中度ARDS患者,评估ECCO2R辅助超保护性通气的可行性与安全性。
- 8小时达到超保护性通气且PaCO2升高≤20%、pH>7.30的患者比例为78%(74/95,95%CI 68-89%);24小时为82%(78/95,95%CI 76-88%)。
- ECCO2R维持5[3-8]天;报告6例严重不良事件,其中2例归因于ECCO2R(脑出血和气胸);39%的患者发生ECCO2R相关不良事件。
- 第28天存活69例(73%),出院存活59例(62%)。
证据类型、等级与局限
- 证据类型:前瞻性多中心国际2期研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,使用ECCO2R辅助超保护性通气是可行的,但需随机临床试验评估总体获益与危害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We assessed feasibility and safety of extracorporeal carbon dioxide removal (ECCO2R) to facilitate ultra-protective ventilation (VT 4 mL/kg and PPLAT ≤ 25 cmH2O) in patients with moderate acute respiratory distress syndrome (ARDS).
METHODS: Prospective multicenter international phase 2 study. Primary endpoint was the proportion of patients achieving ultra-protective ventilation with PaCO2 not increasing more than 20% from baseline, and arterial pH > 7.30. Severe adverse events (SAE) and ECCO2R-related adverse events (ECCO2R-AE) were reported to an independent data and safety monitoring board. We used lower CO2 extraction and higher CO2 extraction devices (membrane lung cross-sectional area 0.59 vs. 1.30 m2; flow 300-500 mL/min vs. 800-1000 mL/min, respectively).
RESULTS: Ninety-five patients were enrolled. The proportion of patients who achieved ultra-protective settings by 8 h and 24 h was 78% (74 out of 95 patients; 95% confidence interval 68-89%) and 82% (78 out of 95 patients; 95% confidence interval 76-88%), respectively. ECCO2R was maintained for 5 [3-8] days. Six SAEs were reported; two of them were attributed to ECCO2R (brain hemorrhage and pneumothorax). ECCO2R-AEs were reported in 39% of the patients. A total of 69 patients (73%) were alive at day 28. Fifty-nine patients (62%) were alive at hospital discharge.
CONCLUSIONS: Use of ECCO2R to facilitate ultra-protective ventilation was feasible. A randomized clinical trial is required to assess the overall benefits and harms. CLINICALTRIALS.GOV: NCT02282657.
参考来源
- Combes A, Fanelli V, Pham T, et al. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med. 2019. PMID: 30790030. doi:10.1007/s00134-019-05567-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。